Rosco OncoLatina

Ruleta de Palabras

Jugadas 3

Crear copia

Sobre esta actividad

Rosco OncoLatina

Creada por

Lorena Moran

Argentina

Descarga la versión para jugar en papel

Top 10 resultados

#	Jugador	Acierto	tiempo
1	Lorena Moran 11 de Febrero de 2026	% 0	00:05

¿Quieres aparecer en el Top 10 de este juego? Inicia sesión para identificarte.

Crea tu propio juego gratis desde nuestro creador de juegos

Compite contra tus amigos para ver quien consigue la mejor puntuación en esta actividad

Crear reto

Jugadores de futbol

Arnau Aspas

España

(46)

Jugadores de futbol de todo el mundo
ruleta de brawl stars

Andres NM

España

(99)

para pross
JUEGO PASAPALABRA ROSCO 2

Maite María

España

(913)

Juego pasapalabra.
ROSCO VIRTUAL

y h

Chile

(106)

Este rosco es de temática libre, para alumnos de 5to y 6to año básico.
Equipos de futbol

Juan Gabry Paredes

Ecuador

(107)

Equipos de futbol profesionales


Rosco OncoLatinaVersión en línea Rosco OncoLatina por Lorena Moran A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Empieza por A The most common age group in which AML is diagnosed, typically associated with different biology and prognosis compared to pediatric cases. Empieza por B A leading hematology journal publishing pivotal AML trials and ELN updates. Empieza por C A measurable clinical endpoint indicating disappearance of detectable leukemia after treatment. Empieza por D A potentially life-threatening inflammatory complication associated with IDH inhibitors and differentiating agents. Empieza por E European expert network providing AML genetic risk classification standards. Empieza por F AML patients eligible for intensive induction chemotherapy based on clinical assessment. Empieza por G Prognostic classification in AML based on cytogenetic and molecular abnormalities. Empieza por H Prognostic category defined by adverse cytogenetics or molecular abnormalities according to ELN classification. Empieza por I Oral targeted therapy inhibiting mutant IDH1 in AML. Empieza por J High-impact oncology journal frequently publishing pivotal AML phase III trials. Empieza por K The chromosomal profile used to define cytogenetic prognosis in AML. Empieza por L Clonal malignant disorder of myeloid precursors defined by 20% blasts in bone marrow. Empieza por M Highly sensitive technique used to detect residual leukemic cells after treatment. Empieza por N Frequent hematologic complication in AML patients, either disease-related or treatment-induced, increasing infection risk. Empieza por O Gold-standard survival endpoint measuring time from treatment initiation to death from any cause. Empieza por P Predicted clinical course of AML based on genetic and clinical variables. Empieza por Q Cardiac parameter that must be monitored with certain targeted AML therapies. Empieza por R Return of leukemic blasts after achieving remission. Contiene la S A composite clinical endpoint that may include CR, CRi, and CRh. Empieza por T Three-drug regimen increasingly investigated in molecularly defined AML subgroups. Empieza por U AML patients not eligible for intensive chemotherapy. Empieza por V BCL-2 inhibitor that transformed outcomes in combination with HMAs in elderly AML patients. Contiene la W A laboratory parameter often elevated at AML diagnosis reflecting disease burden. Contiene la X A critical safety parameter in AML therapy that may require dose adjustment or treatment interruption. Empieza por Y Unit of time commonly used to report long-term survival outcomes in AML trials. Contiene la Z An epigenetic regulator gene frequently mutated in AML and under therapeutic investigation.

Rosco OncoLatinaVersión en línea

Rosco OncoLatina

por Lorena Moran

Empieza por A

The most common age group in which AML is diagnosed, typically associated with different biology and prognosis compared to pediatric cases.

Empieza por B

A leading hematology journal publishing pivotal AML trials and ELN updates.

Empieza por C

A measurable clinical endpoint indicating disappearance of detectable leukemia after treatment.

Empieza por D

A potentially life-threatening inflammatory complication associated with IDH inhibitors and differentiating agents.

Empieza por E

European expert network providing AML genetic risk classification standards.

Empieza por F

AML patients eligible for intensive induction chemotherapy based on clinical assessment.

Empieza por G

Prognostic classification in AML based on cytogenetic and molecular abnormalities.

Empieza por H

Prognostic category defined by adverse cytogenetics or molecular abnormalities according to ELN classification.

Empieza por I

Oral targeted therapy inhibiting mutant IDH1 in AML.

Empieza por J

High-impact oncology journal frequently publishing pivotal AML phase III trials.

Empieza por K

The chromosomal profile used to define cytogenetic prognosis in AML.

Empieza por L

Clonal malignant disorder of myeloid precursors defined by 20% blasts in bone marrow.

Empieza por M

Highly sensitive technique used to detect residual leukemic cells after treatment.

Empieza por N

Frequent hematologic complication in AML patients, either disease-related or treatment-induced, increasing infection risk.

Empieza por O

Gold-standard survival endpoint measuring time from treatment initiation to death from any cause.

Empieza por P

Predicted clinical course of AML based on genetic and clinical variables.

Empieza por Q

Cardiac parameter that must be monitored with certain targeted AML therapies.

Empieza por R

Return of leukemic blasts after achieving remission.

Contiene la S

A composite clinical endpoint that may include CR, CRi, and CRh.

Empieza por T

Three-drug regimen increasingly investigated in molecularly defined AML subgroups.

Empieza por U

AML patients not eligible for intensive chemotherapy.

Empieza por V

BCL-2 inhibitor that transformed outcomes in combination with HMAs in elderly AML patients.

Contiene la W

A laboratory parameter often elevated at AML diagnosis reflecting disease burden.

Contiene la X

A critical safety parameter in AML therapy that may require dose adjustment or treatment interruption.

Empieza por Y

Unit of time commonly used to report long-term survival outcomes in AML trials.

Contiene la Z

An epigenetic regulator gene frequently mutated in AML and under therapeutic investigation.

		%
	Anónimo	%
		%
		%

Rosco OncoLatina

Ruleta de Palabras

Sobre esta actividad

Creada por

Descarga la versión para jugar en papel

Top juegos

Ruleta de Palabras

Jugadores de futbol

Ruleta de Palabras

ruleta de brawl stars

Ruleta de Palabras

JUEGO PASAPALABRA ROSCO 2

Ruleta de Palabras

ROSCO VIRTUAL

Ruleta de Palabras

Equipos de futbol

Rosco OncoLatinaVersión en línea

por Lorena Moran

Empieza por A

The most common age group in which AML is diagnosed, typically associated with different biology and prognosis compared to pediatric cases.

Empieza por B

A leading hematology journal publishing pivotal AML trials and ELN updates.

Empieza por C

A measurable clinical endpoint indicating disappearance of detectable leukemia after treatment.

Empieza por D

A potentially life-threatening inflammatory complication associated with IDH inhibitors and differentiating agents.

Empieza por E

European expert network providing AML genetic risk classification standards.

Empieza por F

AML patients eligible for intensive induction chemotherapy based on clinical assessment.

Empieza por G

Prognostic classification in AML based on cytogenetic and molecular abnormalities.

Empieza por H

Prognostic category defined by adverse cytogenetics or molecular abnormalities according to ELN classification.

Empieza por I

Oral targeted therapy inhibiting mutant IDH1 in AML.

Empieza por J

High-impact oncology journal frequently publishing pivotal AML phase III trials.

Empieza por K

The chromosomal profile used to define cytogenetic prognosis in AML.

Empieza por L

Clonal malignant disorder of myeloid precursors defined by 20% blasts in bone marrow.

Empieza por M

Highly sensitive technique used to detect residual leukemic cells after treatment.

Empieza por N

Frequent hematologic complication in AML patients, either disease-related or treatment-induced, increasing infection risk.

Empieza por O

Gold-standard survival endpoint measuring time from treatment initiation to death from any cause.

Empieza por P

Predicted clinical course of AML based on genetic and clinical variables.

Empieza por Q

Cardiac parameter that must be monitored with certain targeted AML therapies.

Empieza por R

Return of leukemic blasts after achieving remission.

Contiene la S

A composite clinical endpoint that may include CR, CRi, and CRh.

Empieza por T

Three-drug regimen increasingly investigated in molecularly defined AML subgroups.

Empieza por U

AML patients not eligible for intensive chemotherapy.

Empieza por V

BCL-2 inhibitor that transformed outcomes in combination with HMAs in elderly AML patients.

Contiene la W

A laboratory parameter often elevated at AML diagnosis reflecting disease burden.

Contiene la X

A critical safety parameter in AML therapy that may require dose adjustment or treatment interruption.

Empieza por Y

Unit of time commonly used to report long-term survival outcomes in AML trials.

Contiene la Z

An epigenetic regulator gene frequently mutated in AML and under therapeutic investigation.